It didn’t take George Scangos very long to find a new role after leaving Biogen as he starts 2017 as the head of a new upstart: Vir Biotechnology.

Neon Therapeutics has started the year with a cash injection that will allow it to move ahead with all three of its development programs in parallel.

Synthetic RNA kit business Synthego has raised $41 million to step up its efforts to make CRISPR gene editing easier and more accurate.

NeRRe Therapeutics has raised £23 million in a Series B backed by new investors Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed.

RaNA Therapeutics has acquired Shire’s mRNA therapy platform, originally developed by its MRT employees, who have also now joined RaNA as part of the deal.

Versant has its sixth venture fund, with a cool $400 million, as the VC eyes injecting the cash into as many as 25 biotechs.

Ascletis has raised $100 million in a second-round financing as it prepares for the launch of its first commercial product.

Biotech, like all other industries and the British public, is no closer to knowing what life will look like post-Brexit than it was on June 24.

Venture Capital